Literature DB >> 33229341

Dysregulated Glutamate Transporter SLC1A1 Propels Cystine Uptake via Xc- for Glutathione Synthesis in Lung Cancer.

Wenzheng Guo1,2, Kaimi Li1,3, Beibei Sun4, Dongliang Xu1,5, Lingfeng Tong5, Huijing Yin1, Yueling Liao1,5, Hongyong Song1,5, Tong Wang1,5, Bo Jing1,5, Min Hu1,5, Shuli Liu6, Yanbin Kuang7, Jing Ling8, Qi Li8, Yadi Wu9, Qi Wang7, Feng Yao10, Binhua P Zhou9, Shu-Hai Lin11, Jiong Deng12,4,5.   

Abstract

Cancer cells need to generate large amounts of glutathione (GSH) to buffer oxidative stress during tumor development. A rate-limiting step for GSH biosynthesis is cystine uptake via a cystine/glutamate antiporter Xc-. Xc- is a sodium-independent antiporter passively driven by concentration gradients from extracellular cystine and intracellular glutamate across the cell membrane. Increased uptake of cystine via Xc- in cancer cells increases the level of extracellular glutamate, which would subsequently restrain cystine uptake via Xc-. Cancer cells must therefore evolve a mechanism to overcome this negative feedback regulation. In this study, we report that glutamate transporters, in particular SLC1A1, are tightly intertwined with cystine uptake and GSH biosynthesis in lung cancer cells. Dysregulated SLC1A1, a sodium-dependent glutamate carrier, actively recycled extracellular glutamate into cells, which enhanced the efficiency of cystine uptake via Xc- and GSH biosynthesis as measured by stable isotope-assisted metabolomics. Conversely, depletion of glutamate transporter SLC1A1 increased extracellular glutamate, which inhibited cystine uptake, blocked GSH synthesis, and induced oxidative stress-mediated cell death or growth inhibition. Moreover, glutamate transporters were frequently upregulated in tissue samples of patients with non-small cell lung cancer. Taken together, active uptake of glutamate via SLC1A1 propels cystine uptake via Xc- for GSH biosynthesis in lung tumorigenesis. SIGNIFICANCE: Cellular GSH in cancer cells is not only determined by upregulated Xc- but also by dysregulated glutamate transporters, which provide additional targets for therapeutic intervention. ©2020 American Association for Cancer Research.

Entities:  

Year:  2020        PMID: 33229341     DOI: 10.1158/0008-5472.CAN-20-0617

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  8 in total

Review 1.  Metabolite transporters as regulators of macrophage polarization.

Authors:  Jingwen Cheng; Weiwei Cai; Shiye Zong; Yun Yu; Fang Wei
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2021-12-01       Impact factor: 3.000

Review 2.  Amino Acid Transporters on the Guard of Cell Genome and Epigenome.

Authors:  Uğur Kahya; Ayşe Sedef Köseer; Anna Dubrovska
Journal:  Cancers (Basel)       Date:  2021-01-02       Impact factor: 6.639

3.  Radiotracer stereochemistry affects substrate affinity and kinetics for improved imaging of system xC - in tumors.

Authors:  Hannah E Greenwood; Richard Edwards; Norman Koglin; Mathias Berndt; Friedrich Baark; Jana Kim; George Firth; Eman Khalil; Andre Mueller; Timothy H Witney
Journal:  Theranostics       Date:  2022-01-24       Impact factor: 11.556

4.  Comprehensive Analysis of Potential Correlation Between Solute Carrier 1A (SLC1A) Family and Lung Adenocarcinoma.

Authors:  Xiaowu Zhong; Lihua Yao; Lei Xu; Qiang Ma; Guangcheng Huang; Miyuan Yang; Chuanli Gao; Jibing Cheng; Xi Zhou; Qinrong Li; Xiaolan Guo
Journal:  Int J Gen Med       Date:  2022-02-24

5.  Metabolomics analysis identifies glutamic acid and cystine imbalances in COVID-19 patients without comorbid conditions. Implications on redox homeostasis and COVID-19 pathophysiology.

Authors:  José C Páez-Franco; José L Maravillas-Montero; Nancy R Mejía-Domínguez; Jiram Torres-Ruiz; Karla M Tamez-Torres; Alfredo Pérez-Fragoso; Juan Manuel Germán-Acacio; Alfredo Ponce-de-León; Diana Gómez-Martín; Alfredo Ulloa-Aguirre
Journal:  PLoS One       Date:  2022-09-20       Impact factor: 3.752

6.  Levistilide a Induces Ferroptosis by Activating the Nrf2/HO-1 Signaling Pathway in Breast Cancer Cells.

Authors:  Shangwen Jing; Yantong Lu; Jing Zhang; Yan Ren; Yousheng Mo; Dongdong Liu; Lining Duan; Zhongyu Yuan; Changjun Wang; Qi Wang
Journal:  Drug Des Devel Ther       Date:  2022-09-07       Impact factor: 4.319

7.  Versatile Nano-PROTAC-Induced Epigenetic Reader Degradation for Efficient Lung Cancer Therapy.

Authors:  Huan-Tian Zhang; Rui Peng; Sheng Chen; Ao Shen; Lixin Zhao; Wang Tang; Xiao-He Wang; Zhen-Yan Li; Zhen-Gang Zha; Mengmeng Yi; Lingmin Zhang
Journal:  Adv Sci (Weinh)       Date:  2022-08-21       Impact factor: 17.521

Review 8.  Therapeutic Potential of Selenium in Glioblastoma.

Authors:  Eduard Yakubov; Thomas Eibl; Alexander Hammer; Markus Holtmannspötter; Nicolai Savaskan; Hans-Herbert Steiner
Journal:  Front Neurosci       Date:  2021-05-28       Impact factor: 5.152

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.